Market Overview

MPM Capital Expands its Team of Executive Partners and Entrepreneurs with the Appointments of Biotech Leaders Detlev Biniszkiewicz and Scott Chappel


MPM Capital is pleased to announce the recent appointments of Detlev
Biniszkiewicz, Ph.D. and Scott Chappel, Ph.D. as members of its
accomplished team of Executive Partners and entrepreneurs. Highly
skilled senior biopharma leaders, Dr. Biniszkiewicz and Dr. Chappel
bring decades of biotech experience and oncology and immuno-oncology
research expertise to their respective roles. As Executive Partners they
are responsible for identifying and evaluating new oncology investment
opportunities and providing operational and strategic oversight of MPM's
portfolio as well as taking on leadership roles within these companies.

"We're thrilled that Detlev and Scott have joined MPM. The breadth of
their biopharma leadership and operations experience combined with the
depth of their scientific background supports MPM's goal to discover the
latest breakthrough science, build successful companies and deliver
therapies to cure cancers and diseases with high unmet need," said
Ansbert Gadicke, M.D., co-founder and Managing Director of MPM Capital.

Prior to joining MPM, Drs. Biniszkiewicz and Chappel held senior
executive roles at Surface Oncology (NASDAQ:SURF), an immuno-oncology
company developing next-generation antibody therapies that target the
tumor microenvironment. Dr. Biniszkiewicz was President and CEO and led
the company's growth and transformation through to clinical-stage and
guided preparations for its initial public offering, which took place
earlier this year. Dr. Chappel was a founder and Chief Technology
Officer and oversaw all antibody generation, engineering, production,
characterization and manufacturing as well as all preclinical
IND-enabling studies.

"The innovation in oncology and immuno-oncology is transforming the
cancer treatment landscape at a rapid pace and the potential curative
impact of these new treatments is increasing just as quickly," commented
Luke Evnin, Ph.D., co-founder and Managing Director at MPM. "The
accelerated rate of drug discovery demands staying ahead of the curve,
and Detlev and Scott have the research, drug development, and business
acumen to help MPM continue to do this."

Prior to Surface Oncology, Dr. Biniszkiewicz was Vice President of
Strategy in AstraZeneca's Oncology Unit and was part of the oncology
leadership team that developed Lynparza® and Tagrisso® – two innovative
medicines that help thousands of patients suffering from cancer. His
group transformed the firm's oncology pipeline through numerous
licensing deals, clinical alliances and academic collaborations. He has
also held multiple roles at Novartis including Global Head of Portfolio
Management and Analysis, where his group provided oversight of Novartis'
research and early development portfolio.

"MPM is one of only a few life-science venture firms primarily focused
on investing in early-stage oncology, and we share the same passion to
transform the outcomes and well-being of patients suffering from
cancer," noted Dr. Biniszkiewicz. "I am excited to be a part of MPM and
look forward to building and leading innovative companies seeking to
develop novel cancer therapies and possible cures."

With a track record of directing research that has led to several
FDA-approved biological products and founding and leading companies that
develop novel therapies in oncology and other areas, Dr. Chappel, in
addition to his responsibilities at MPM, has been appointed as Chief
Scientific Officer (CSO) at MPM portfolio company iTeos Therapeutics.
There he is responsible for expanding the company's pipeline and leading
the preclinical development of its best-in-class immuno-oncology
programs. Prior to Surface Oncology, he was a founder and CSO at Arteaus
Therapeutics (acquired by Eli Lilly in 2014) and Tokai Pharmaceuticals,
where he developed an oral therapeutic for the treatment of prostate
cancer. Prior to Tokai, he held roles as a Senior Vice President of
Research at Dyax and as a Chief Scientist at Serono.

"I am thrilled to be part of MPM and contribute to its efforts to
discover and develop breakthrough oncology therapies," commented Dr.
Chappel. "I am impressed by MPM's Executive Partner model which helps
guide its portfolio to successful exit with a team of proven industry
experts, scientists and entrepreneurs. And as the newly appointed CSO of
MPM portfolio company, iTeos Therapeutics, I look forward to advancing
its promising immuno-oncology pipeline and transitioning its programs
into the clinic."

Dr. Biniszkiewicz began his career as a Principal at the Boston
Consulting Group and performed his academic research with Rudolf
Jaenisch, M.D. at the Whitehead Institute at the Massachusetts Institute
of Technology in Cambridge, MA. Dr. Chappel received his Ph.D. in
Neuroscience from the University of Maryland School of Medicine and has
authored or co-authored more than 65 peer-reviewed scientific
publications and been named inventor on 19 issued U.S. patents.

About MPM Capital
MPM Capital is a healthcare investment
firm founding and investing in life sciences companies that seek to cure
major diseases by translating scientific innovations into positive
clinical outcomes. MPM invests in breakthrough therapeutics, with a
focus on oncology. With its experienced and dedicated team of investment
professionals, executive partners, entrepreneurs and scientific advisory
board members, MPM is powering novel medical breakthroughs that
transform patients' lives. The firm's innovative approach to investing
includes a crossover strategy (both public and private equities), where
a portion of profits and royalties are donated to cancer care and
research. The firm has partnerships with the American Association for
Cancer Research and the UBS Optimus Foundation. It also has a
philanthropy-investment opportunity involving Dana-Farber Cancer
Institute. For further information, please visit

View Comments and Join the Discussion!